Valsartan pharmacokinetics in patients with controlled and uncontrolled arterial hypertension
https://doi.org/10.37489/2587-7836-2025-1-69-75
EDN: XGAUKX
Abstract
Relevance. Arterial hypertension (AH) is widespread throughout the world. Unfortunately, only a small proportion of patients achieve target blood pressure (BP). One of the possible reasons for the ineffectiveness of AH treatment is the pharmacokinetics of antihypertensive drugs.
Objective. To test valsartan pharmacokinetics in patients with AH.
Material and methods. An open cohort study was conducted. The analysis included 28 patients, including 15 (53.6 %) with uncontrolled AH. All patients regularly took valsartan, amlodipine, indapamide for a month. In the morning before and 2 hours after taking valsartan, venous blood samples were taken from all patients to assess its concentration using high-performance liquid chromatography with tandem mass spectrometry.
Results. Patients of the two groups were comparable in terms of major comorbidities. C0h and C2h of valsartan did not statistically differ in patients with controlled and uncontrolled AH. In 39.3 % of patients, C0h and C2h of valsartan were within the therapeutic range (TD). In 50 % of patients, C0h did not reach the lower limit of TD, and in three patients, the concentration of valsartan exceeded the upper limit of TD, in one of them it exceeded the upper limit of TD almost three times. In 13 patients for whom valsartan was not recommended, it was found in trace amounts.
Conclusion. Thus, to improve the efficacy and safety of valsartan therapy, it is advisable to monitor its concentration in the blood serum.
About the Authors
S. V. Seleznev
Ryazan State Medical University
Russian Federation
Russian Federation
Sergey V. Seleznev — PhD, Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Hospital Therapy with a Course in Medical and Social Expertise, Ryazan State Medical University.
Ryazan
P. Yu. Mylnikov
Ryazan State Medical University
Russian Federation
Russian Federation
Pavel Yu. Mylnikov — PhD, Cand. Sci. (Biol.), Associate Professor of the Department of Pharmacology Ryazan State Medical University.
Ryazan
A. V. Shchulkin
Ryazan State Medical University
Russian Federation
Russian Federation
Aleksey V. Shchulkin — PhD, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Pharmacology, Ryazan State Medical University.
Ryazan
References
1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151.
2. Balanova YA, Shalnova SA, Imaeva AE. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-466. (In Russ.). doi: 10.20996/1819-6446-2019-15-4-450-466.
3. Fang J, Alderman MH, Keenan NL, et al. Hypertension control at physicians' offices in the United States. Am J Hypertens. 2008 Feb;21(2):136-42. doi: 10.1038/ajh.2007.35.
4. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009 May;27(5):963-75. doi: 10.1097/hjh.0b013e3283282f65.
5. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8.
6. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14; 360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8.
7. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014 Dec;32(12):2285-95. doi: 10.1097/HJH.0000000000000378.
8. Punt AM, Stienstra NA, van Kleef MEA, et al. Screening of cardiovascular agents in plasma with LC-MS/MS: A valuable tool for objective drug adherence assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jul 15;1121:103-110. doi: 10.1016/j.jchromb.2019.05.013.
9. Seleznev SV, Kosyakov AV, Mylnikov PYu, et al. Pharmacokinetics of amlodipine in patients with arterial hypertension. Doctor.Ru. 2024;23(1):27-32. (In Russ.). doi: 10.31550/1727-2378-2024-23-1-27-32.
10. Seleznev SV, Shhulkin AV, Kosyakov AV, et al. Farmakokinetika lizinoprila u pacientov s kontroliruemoj i nekontroliruemoj arterial`noj gipertenziej. Nauchno-medicinskij vestnik Central`nogo Chernozem`ya. 2023;24(4):25-34. (In Russ.). doi: 10.18499/1990-472X-2023-24-4-[%]p.
11. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). doi: 10.15829/1560-4071-2020-3-3786.
12. Mylnikov PYu, Shchulkin AV, Seleznev SV, et al. Development and validation of a method for quantitative determination of lisinopril, indapamide, metoprolol, valsartan and amlodipine in human serum by HPLC-MS/MS. Chemical and Pharmaceutical Journal. 2024;58(3):49-53. (In Russ.). doi: 10.30906/0023-1134-2024-58-3-49-53.
13. Sutherland JJ, Morrison RD, McNaughton CD, et al. Assessment of Patient Medication Adherence, Medical Record Accuracy, and Medication Blood Concentrations for Prescription and Over-the-Counter Medications. JAMA Netw Open. 2018 Nov 2;1(7):e184196. doi: 10.1001/jamanetworkopen.2018.4196.
14. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011. Apr 19;123(15): 1611-21. doi: 10.1161/CIRCULATIONAHA.110.983874.
15. Leonova MV. Klinicheskaya farmakologiya antagonistov receptorov AT II: osobennosti valsartana. Medicinskij sovet. 2014;(17):66-71. (In Russ.).
16. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86. doi: 10.1038/sj.jhh.1000991.
17. Waldmeier F, Flesch G, Müller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997 Jan;27(1):59-71. doi: 10.1080/004982597240767.
18. Cabaleiro T, Román M, Ochoa D, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013 Jan;41(1):224-9. doi: 10.1124/dmd.112.046292.
19. Ward N. The impact of intestinal failure on oral drug absorption: a review. J Gastrointest Surg. 2010 Jun;14(6):1045-51. doi: 10.1007/s11605-009-1151-9.
20. McAlister FA, Zhang J, Tonelli M, et al. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. CMAJ. 2011 Apr 5;183(6):655-62. doi: 10.1503/cmaj.101333.
Review
For citations:
Seleznev S.V., Mylnikov P.Yu., Shchulkin A.V. Valsartan pharmacokinetics in patients with controlled and uncontrolled arterial hypertension. Pharmacokinetics and Pharmacodynamics. 2025;(1):69-75. (In Russ.) https://doi.org/10.37489/2587-7836-2025-1-69-75. EDN: XGAUKX
Views:
104
Email this article 